Mary Herbert

Mary Herbert

Auto-generated profile, based on publicly available information

Mary Herbert

Newcastle Fertility Centre at Life, International Centre for Life, Newcastle upon Tyne, UK

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 April 2010 in Nature
Verified
Journal Article
Open access
PDF file
LCLyndsey Craven
Lyndsey Craven
HTHelen A. Tuppen
Helen A. Tuppen
GGGareth D. Greggains
Gareth D. Greggains
SHStephen J. Harbottle
Stephen J. Harbottle
JMJulie L. Murphy
Julie L. Murphy
DTDouglass M. Turnbull
Douglass M. Turnbull
Mitochondrial DNA (mtDNA) mutations passed down from a mother to offspring are a common cause of genetic disease, including neurological, muscle and heart problems, deafness and type 2 diabetes. It was shown recently in non-human primates that nuclear transfer techniques can prevent their transmission. Now, that proof-of-principle work has been extended to human embryos (see News, http://go.nature.com/xqgWXf ). A multi-department team based at Newcastle University transferred pronuclei between human zygotes, and obtained onward development to the blastocyst stage in vitro. Carry-over of donor zygote mtDNA is minimal, so the technique could potentially prevent the transmission of mtDNA disease in humans. Mutations in mitochondrial DNA (mtDNA) are a common cause of human genetic disease. It has been shown in non-human primates that nuclear transfer techniques might be an approach to prevent the transmission of mtDNA mutations. The proof of principle has now been extended to human embryos. Pronuclei were transferred between human zygotes, which developed onwards to the blastocyst stage in vitro. Carry-over of mtDNA from the donor zygotes to the recipients was minimal. Mutations in mitochondrial DNA (mtDNA) are a common cause of genetic disease. Pathogenic mutations in mtDNA are detected in approximately 1 in 250 live births1,2,3 and at least 1 in 10,000 adults in the UK are affected by mtDNA disease4. Treatment options for patients with mtDNA disease are extremely limited and are predominantly supportive in nature. Mitochondrial DNA is transmitted maternally and it has been proposed that nuclear transfer techniques may be an approach for the prevention of transmission of human mtDNA disease5,6. Here we show that transfer of pronuclei between abnormally fertilized human zygotes results in minimal carry-over of donor zygote mtDNA and is compatible with onward development to the blastocyst stage in vitro. By optimizing the procedure we found the average level of carry-over after transfer of two pronuclei is less than 2.0%, with many of the embryos containing no detectable donor mtDNA. We believe that pronuclear transfer between zygotes, as well as the recently described metaphase II spindle transfer, has the potential to prevent the transmission of mtDNA disease in humans.

1 September 2010 in Current Biology
Verified
Journal Article
Closed access
LLLisa Martine Lister
Lisa Martine Lister
AKAnna Kouznetsova
Anna Kouznetsova
LHLouise Ann Hyslop
Louise Ann Hyslop
DKDimitrios Kalleas
Dimitrios Kalleas
SPSarah Louise Pace
Sarah Louise Pace
MHMary Herbert
Mary Herbert

1 September 2005 in Stem Cells
Verified
Journal Article
Closed access
PDF file
LHLouise Hyslop
Louise Hyslop
MSMiodrag Stojkovic
Miodrag Stojkovic
LALyle Armstrong
Lyle Armstrong
TWTheresia Walter
Theresia Walter
PSPetra Stojkovic
Petra Stojkovic
MLMajlinda Lako
Majlinda Lako
The homeobox transcription factor Nanog has been proposed to play a crucial role in the maintenance of the undifferentiated state of murine embryonic

8 June 2016 in Nature
Verified
Journal Article
Open access
PDF file
LHLouise A. Hyslop
Louise A. Hyslop
PBPaul Blakeley
Paul Blakeley
LCLyndsey Craven
Lyndsey Craven
JRJessica Richardson
Jessica Richardson
NFNorah M. E. Fogarty
Norah M. E. Fogarty
MHMary Herbert
Mary Herbert
Preclinical evaluation and optimization of mitochondrial replacement therapy reveals that a modified form of pronuclear transfer is likely to give rise to normal pregnancies with a reduced risk of mitochondrial DNA disease, but may need further modification to eradicate the disease in all cases. These authors report a preclinical evaluation and optimization of mitochondria replacement therapy using pronuclear transfer. The influence of different parameters and manipulations is evaluated in normally fertilized human embryos, and the improved protocol is shown to produce blastocysts with a low level of mitochondrial carryover. The results highlight the need for continued optimization and monitoring of mitochondria replacement therapy techniques for future human application. Mitochondrial DNA (mtDNA) mutations are maternally inherited and are associated with a broad range of debilitating and fatal diseases1. Reproductive technologies designed to uncouple the inheritance of mtDNA from nuclear DNA may enable affected women to have a genetically related child with a greatly reduced risk of mtDNA disease. Here we report the first preclinical studies on pronuclear transplantation (PNT). Surprisingly, techniques used in proof-of-concept studies involving abnormally fertilized human zygotes2 were not well tolerated by normally fertilized zygotes. We have therefore developed an alternative approach based on transplanting pronuclei shortly after completion of meiosis rather than shortly before the first mitotic division. This promotes efficient development to the blastocyst stage with no detectable effect on aneuploidy or gene expression. After optimization, mtDNA carryover was reduced to <2% in the majority (79%) of PNT blastocysts. The importance of reducing carryover to the lowest possible levels is highlighted by a progressive increase in heteroplasmy in a stem cell line derived from a PNT blastocyst with 4% mtDNA carryover. We conclude that PNT has the potential to reduce the risk of mtDNA disease, but it may not guarantee prevention.

1 April 2015 in Cold Spring Harbor Perspectives in Biology
Verified
Journal Article
Closed access
PDF file
MHMary Herbert
Mary Herbert
DKDimitrios Kalleas
Dimitrios Kalleas
DCDaniel Cooney
Daniel Cooney
MLMahdi Lamb
Mahdi Lamb
LLLisa Lister
Lisa Lister
In most organisms, genome haploidization requires reciprocal DNA exchanges (crossovers) between replicated parental homologs to form bivalent chromosomes. These are resolved to their four constituent chromatids during two meiotic divisions. In female mammals, bivalents are formed during fetal life and remain intact until shortly before ovulation. Extending this period beyond ∼35 years greatly increases the risk of aneuploidy in human oocytes, resulting in a dramatic increase in infertility, miscarriage, and birth defects, most notably trisomy 21. Bivalent chromosomes are stabilized by cohesion between sister chromatids, which is mediated by the cohesin complex. In mouse oocytes, cohesin becomes depleted from chromosomes during female aging. Consistent with this, premature loss of centromeric cohesion is a major source of aneuploidy in oocytes from older women. Here, we propose a mechanistic framework to reconcile data from genetic studies on human trisomy and oocytes with recent advances in our understanding of the molecular mechanisms of chromosome segregation during meiosis in model organisms.

15 January 2005 in Genes & Development
Verified
Journal Article
Open access
PDF file
HHH. Homer
H. Homer
Alex McdougallAlex Mcdougall
Alex Mcdougall
MLMark Levasseur
Mark Levasseur
KYKatie Yallop
Katie Yallop
AMAlison P. Murdoch
Alison P. Murdoch
MHMary Herbert
Mary Herbert
In mitosis, the spindle checkpoint protein Mad2 averts aneuploidy by delaying anaphase onset until chromosomes align. Here we show that depletion of Mad2 in meiosis I mouse oocytes induced an increased incidence of aneuploidy. Proteolysis of cyclin B and securin commenced earlier in Mad2-depleted oocytes, resulting in a shortened duration of meiosis I. Furthermore, overexpression of Mad2 inhibited homolog disjunction. We conclude that Mad2 delays the onset of cyclin B and securin degradation and averts aneuploidy during meiosis I in mammalian oocytes. The data suggest a link between trisomies such as Down syndrome and defective oocyte spindle checkpoint function.